INDUCE-2: A Phase I/II, Open-Label, Two-Part Study of Feladilimab in Combination with Tremelimumab in Patients with Advanced Solid Tumors.
Cancer Immunology Immunotherapy（2024）
Key words
Immunotherapy,Biomarkers,Clinical-trial results,Tumor microenvironment,Immunology
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined